NCT01516918 - A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions

Chronic Hepatitis C Virus

Interventions

DRUG

VX-222

tablet, 400-mg twice daily

DRUG

telaprevir

tablet, 1125-mg twice daily

DRUG

ribavirin

tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily

BIOLOGICAL

peginterferon-alfa-2a

subcutaneous injection, 180-mcg, once weekly

Trial Locations (43)

Unknown

Birmingham

San Diego

Englewood

Bradenton

Jacksonville

Tampa

Marietta

Chicago

Indianapolis

Boston

Detroit

Lebanon

Egg Harbor

Manhasset

New York

Rochester

Asheville

Charlotte

Durham

Cincinnati

Providence

Germantown

Arlington

Houston

San Antonio

Norfolk

Madison

Milwaukee

Vancouver

London

Montreal

Cologne

Hamburg

Heidelberg

Hessen

Saschen

Stuttgart

Bialystok

Mysłowice

Wroclaw

London

Plymouth

Scotland

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY